Issue 6/2013
Content (24 Articles)
The role of antioxidants in the era of cardio-oncology
Duncan T. Vincent, Yasmine F. Ibrahim, Michael Graham Espey, Yuichiro J. Suzuki
The VEGF pathway in lung cancer
Michalis Alevizakos, Serafim Kaltsas, Konstantinos N. Syrigos
Differential regulation of sunitinib targets predicts its tumor-type-specific effect on endothelial and/or tumor cell apoptosis
Guilhem Bousquet, Mariana Varna, Irmine Ferreira, Li Wang, Pierre Mongiat-Artus, Christophe Leboeuf, Cédric de Bazelaire, Sandrine Faivre, Philippe Bertheau, Eric Raymond, Stéphane Germain, Anne Janin
Effects of the aldehyde dehydrogenase inhibitor disulfiram on the plasma pharmacokinetics, metabolism, and toxicity of benzaldehyde dimethane sulfonate (NSC281612, DMS612, BEN) in mice
Robert A. Parise, Jan H. Beumer, Dana M. Clausen, Lora H. Rigatti, Judy A. Ziegler, Maura Gasparetto, Clayton A. Smith, Julie L. Eiseman
Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study
Rachel C. Jankowitz, Jame Abraham, Antoinette R. Tan, Steven A. Limentani, Marni B. Tierno, Laura M. Adamson, Marc Buyse, Norman Wolmark, Samuel A. Jacobs
Phase II, open-label trial to assess QTcF effects, pharmacokinetics and antitumor activity of afatinib in patients with relapsed or refractory solid tumors
L. Rhoda Molife, Sarah M. Rudman, Salma Alam, Daniel S.-W. Tan, Hartmut Kristeleit, Gary Middleton, David Propper, Liz Bent, Peter Stopfer, Martina Uttenreuther-Fischer, Gudrun Wallenstein, Johann de Bono, James Spicer
Investigation into CYP3A4-mediated drug–drug interactions on midostaurin in healthy volunteers
Catherine Dutreix, Florence Munarini, Sebastien Lorenzo, Johannes Roesel, Yanfeng Wang
Angiotensin-(1–7) synergizes with colony-stimulating factors in hematopoietic recovery
Kathleen E. Rodgers, Theresa B. Espinoza, Norma Roda, Christopher J. Meeks, Gere S. diZerega
A phase III concurrent chemoradiotherapy trial with cisplatin and paclitaxel or docetaxel or gemcitabine in unresectable non-small cell lung cancer: KASLC 0401
In-Jae Oh, Kyu-Sik Kim, Young-Chul Kim, Hee-Jung Ban, Yong-Soo Kwon, Yu-Il Kim, Sung-Chul Lim, Woong-Ki Chung, Taek-Keun Nam, Joo-Young Song, Mee-Sun Yoon, Sung-Ja Ahn
Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase
Santhosh Palani, Mayankbhai Patel, Jessica Huck, Mengkun Zhang, Suresh K. Balani, Johnny Yang, Susan Chen, Jerome Mettetal, Mark Manfredi, Wen Chyi Shyu, Jeffrey A. Ecsedy, Arijit Chakravarty
Transient severe hyperbilirubinemia after hepatic arterial infusion of oxaliplatin in patients with liver metastases
Sean S. Garcia, Johnique T. Atkins, Gerald S. Falchook, Apostolia M. Tsimberidou, David S. Hong, Meghana V. Trivedi, Razelle Kurzrock
13C-uracil breath test to predict 5-fluorouracil toxicity in gastrointestinal cancer patients
Geraldo Felício Cunha-Junior, Luiz De Marco, Luciana Bastos-Rodrigues, Marina Borges Bolina, Flavia Linhares Martins, Gerson Antonio Pianetti, Isabela Costa Cesar, Luiz Gonzaga Coelho
Goshajinkigan oxaliplatin neurotoxicity evaluation (GONE): a phase 2, multicenter, randomized, double-blind, placebo-controlled trial of goshajinkigan to prevent oxaliplatin-induced neuropathy
Toru Kono, Taishi Hata, Satoshi Morita, Yoshinori Munemoto, Takanori Matsui, Hiroshi Kojima, Hiroyoshi Takemoto, Mutsumi Fukunaga, Naoki Nagata, Mitsuo Shimada, Junichi Sakamoto, Hideyuki Mishima
A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer
Yousuke Nakai, Hiroyuki Isayama, Takashi Sasaki, Naminatsu Takahara, Tsuyoshi Hamada, Rie Uchino, Suguru Mizuno, Koji Miyabayashi, Keisuke Yamamoto, Dai Mohri, Hirofumi Kogure, Natsuyo Yamamoto, Kenji Hirano, Hideaki Ijichi, Keisuke Tateishi, Minoru Tada, Kazuhiko Koike
Phase II trial of erlotinib in patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics
Kohei Motoshima, Yoichi Nakamura, Kazumi Sano, Yoji Ikegami, Takaya Ikeda, Kosuke Mizoguchi, Shinnosuke Takemoto, Minoru Fukuda, Seiji Nagashima, Tetsuya Iida, Kazuhiro Tsukamoto, Shigeru Kohno
Phase 1 study of N 1,N 11-diethylnorspermine (DENSPM) in patients with advanced hepatocellular carcinoma
Lipika Goyal, Jeffrey G. Supko, Jordan Berlin, Lawrence S. Blaszkowsky, Amanda Carpenter, Douglas M. Heuman, Sarah L. Hilderbrand, Keith E. Stuart, Scott Cotler, Neil N. Senzer, Emily Chan, Carl L. Berg, Jeffrey W. Clark, Aram F. Hezel, David P. Ryan, Andrew X. Zhu
A novel antitumor piperazine alkyl compound causes apoptosis by inducing RhoB expression via ROS-mediated c-Abl/p38 MAPK signaling
Kyung-Sook Chung, Gyoonhee Han, Bo-Kyung Kim, Hwan-Mook Kim, Jee Sun Yang, Jiwon Ahn, Kyeong Lee, Kyung-Bin Song, Misun Won
Evaluation of safety parameters and changes in serum concentration in liver transplant recipients treated with doxorubicin during the anhepatic period
Shogo Kobayashi, Hiroshi Wada, Naoki Hama, Hirofumi Akita, Koichi Kawamoto, Hidetoshi Eguchi, Koji Umeshita, Yuichiro Doki, Masaki Mori, Hiroaki Nagano
Flow cytometric chemosensitivity assay using JC-1, a sensor of mitochondrial transmembrane potential, in acute leukemia
Tomoko Yokosuka, Hiroaki Goto, Hisaki Fujii, Takuya Naruto, Masanobu Takeuchi, Reo Tanoshima, Hiromi Kato, Masakatsu Yanagimachi, Ryosuke Kajiwara, Shumpei Yokota
A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours
Laura Horsley, Jeff Cummings, Mark Middleton, Tim Ward, Alison Backen, Andrew Clamp, Martin Dawson, Hayley Farmer, Nita Fisher, Gavin Halbert, Sarah Halford, Adrian Harris, Jurjees Hasan, Philip Hogg, Gireesh Kumaran, Ross Little, Geoff J. M. Parker, Paula Potter, Mark Saunders, Caleb Roberts, Danielle Shaw, Nigel Smith, Jon Smythe, Andrew Taylor, Helen Turner, Yvonne Watson, Caroline Dive, Gordon C. Jayson
Phase II study of concurrent thoracic radiotherapy in combination with weekly paclitaxel plus carboplatin in locally advanced non-small cell lung cancer: LOGIK0401
Koichi Takayama, Koji Inoue, Shoji Tokunaga, Takemasa Matsumoto, Tsukasa Oshima, Masayuki Kawasaki, Tomotoshi Imanaga, Mutsuo Kuba, Masafumi Takeshita, Taishi Harada, Yoshiyuki Shioyama, Yoichi Nakanishi
An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs
Vincent Launay-Vacher
Pharmacokinetics of high-dose simvastatin in refractory and relapsed chronic lymphocytic leukemia patients
Tamer A. Ahmed, John Hayslip, Markos Leggas
Erratum to: Between-course targeting of methotrexate exposure using pharmacokinetically guided dosage adjustments
Jennifer L. Pauley, John C. Panetta, Kristine R. Crews, Deqing Pei, Cheng Cheng, John McCormick, Scott C. Howard, John T. Sandlund, Sima Jeha, Raul Ribeiro, Jeffrey Rubnitz, Ching-Hon Pui, William E. Evans, Mary V. Relling